SWOG clinical trial number
CTSU/E2902

A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure or Patients Over Age 60 in First Remission

Closed
Phase
Abbreviated Title
Phase III AML in Second or Subsequent Remission or in Remission after Primary Induction Failure
Activated
10/01/2004
Closed
06/01/2007
Participants
CTSU

Research committees

Leukemia

Treatment

R115777

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group participated in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information.

Publication Information Expand/Collapse

2021

Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial

S Luger;V Wang;J Rowe;M Litzow;E Paietta;R Kettering;H Lazarus;W Rybka;M Craig;J Karp;B Cooper;A Makary;L Kaminer;F Appelbaum;R Larson;M Tallman Leukemia Research Dec;111:106736

PMid: PMID34773794 | PMC number: PMC8643322

2015

Tipifarnib as maintenance therapy In acute myeloid leukemia (AML) improves survival in women with high risk disease. Results of the phase III intergroup trial E2902

S Luger;X Yao;E Paietta;R Ketterling;W Rybka;M Litzow;JM Rowe;R Larson;F Appelbaum;M Tallman Blood 126(23):1308; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), poster;

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/A042001

A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Research Committee(s)
Leukemia
Activated
02/27/2023
Open
Phase
SWOG Clinical Trial Number
S1925

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12/14/2020
Accrual
43%
Open
Phase
SWOG Clinical Trial Number
CTSU/AALL1821

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
Research Committee(s)
Leukemia
Activated
12/04/2020
Open